UCB Pharma

First report 29 Apr 2014•Latest report 29 Apr 2014

Reports, concerns and published responses

Reports naming this recipient by issue year.

* 2026 is projected from reports observed to 7 Sep 2026.

Statements from UCB Pharma linked to the concerns in each report. Select any concern, action or position to view the source wording.

29 Apr2014
Avon
Concerns raised1
1. Failure to draw physicians’ attention to the possibility of such an occurrence in drug literature or BNF entries
No linked response statements
No action or position from this recipient is clearly linked to the concerns in this report.
AI-generated summary

Dafydd Rhys WATTS · Prevention of Future Deaths report

This summary was generated using AI from the published report. Please read the original report for the complete account.

Report summary

Dafydd Rhys WATTS died of eosinophilic pericarditis and DRESS syndrome following treatment with levetiracetam for epilepsy. The report raised concern that the possibility of this exceptionally rare reaction and death was not drawn to physicians’ attention in the drug literature or BNF entry.

Read the report on judiciary.uk
Source evidence
How this individual concern was interpreted
PFD Monitor created a concise, searchable interpretation from the report wording shown below. The report was sent to UCB Pharma; that does not assign responsibility.
PFD Monitor interpretation
Failure to draw physicians’ attention to the possibility of such an occurrence in drug literature or BNF entries
Wider context from the report
“Although the evidence suggests that this is only the fourth such death documented it appears that the possibility (albeit remote) of such an occurrence is not drawn to physicians attention in the drug literature or in the BNF entry. ”
Open source report

Information checked against published PFD reports and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Data last updated 7 September 2026